Home > Quotes > CCXI > Guru Analysis > Kenneth Fisher

Kenneth Fisher Guru Analysis for ChemoCentryx, Inc.

Get CCXI Alerts
*Delayed - data as of Nov. 25, 2015  -  Find a broker to begin trading CCXI now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
Basic Chart Interactive Chart
Company Headlines Press Releases Market Stream
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Assessments & Analysis Based on November 24, 2015 close price: $7.24

  for the Price/Sales Investor based on the criteria of Kenneth Fisher. Return to CCXI Guru Analysis

All Star Guru Scorecard

Source Go Chart %
Peter Lynch 0%
Benjamin Graham 43%
Validea 14%
Motley Fool 56%
David Dreman 21%
Martin Zweig 15%
Kenneth Fisher 40%
James P. O'Shaughnessy 25%

Detailed Analysis

Guru Score: 40%


The prospective company should have a low Price/Sales ratio. However, CCXI's P/S is not available which means an opinion cannot be rendered at the present time on this variable. This is the most important variable according to this methodology, and therefore the remainder of the analysis will be provided for informational purposes.


Less debt equals less risk according to this methodology. CCXI's Debt/Equity of 0.00% is exceptional, thus passing the test.


This methodology considers companies in the Technology and Medical sectors to be attractive if they have low Price/Research ratios. CCXI is neither a Technology nor Medical company. Therefore the Price/Research ratio is not available and, hence, not much emphasis should be placed on this particular variable.

PRELIMINARY GRADE: No Interest in CCXI At this Point

Is CCXI a "Super Stock"? NO


This methodology looks for companies that have an inflation adjusted EPS growth rate greater than 15%. CCXI's inflation adjusted EPS growth rate is not available. Hence, this methodology cannot analyze this criterion at the present time.


This methodology looks for companies that have a positive free cash per share. Companies should have enough free cash available to sustain three years of losses. This is based on the premise that companies without cash will soon be out of business. CCXI's free cash per share of -1.08 fails this criterion.


This methodology looks for companies that have an average net profit margin of 5% or greater over a three year period. CCXI's three year net profit margin, which averages -458.03%, does not pass this criterion.

The names of individual investment advisors (i.e., the 'gurus') appearing ON THIS WEBSITE are for identification purposes ONLY. The names are used to identify the methodology as derived from the guru's published sources. The names of the individual gurus are not intended to suggest or imply any affiliation with or endorsement of, or even any agreement with the information displayed on this website personally by such gurus, or any knowledge or approval by such persons of the content on this website. All trademarks, service marks and trade names appearing on this website are the property of their respective owners, and are likewise used for identification purposes only.

The NASDAQ Stock Market, Inc. ("NASDAQ"), its affiliates, third party information providers, or any of these entities' officers, employees, directors, or agents have not: (1) passed on the merit of the information provided on this website or on any of these securities; or (2) endorsed or sponsored any of these securities. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED. The information contained on this website is provided for informational purposes only. See Full Disclaimer Below
See Full Disclaimer
The Validea Market Legends ETF (VALX)